Cartesian Therapeutics (RNAC) reported a “watershed moment” for its autoimmune-disease focused CAR-T treatment on Tuesday, but the biotech stock plunged in premarket trades. ↑ X NOW PLAYING CRSP Stock On Wild Ride After FDA’s Historic Approval. These Gene Editing Treatments Could Come Next. The biotech company tested its drug, Descartes-08, in patients with generalized myasthenia […]